WO2003093795A2 - Device and method for analytical cell imaging - Google Patents
Device and method for analytical cell imaging Download PDFInfo
- Publication number
- WO2003093795A2 WO2003093795A2 PCT/US2003/013842 US0313842W WO03093795A2 WO 2003093795 A2 WO2003093795 A2 WO 2003093795A2 US 0313842 W US0313842 W US 0313842W WO 03093795 A2 WO03093795 A2 WO 03093795A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- illumination
- sample
- group
- sample chamber
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 42
- 238000003384 imaging method Methods 0.000 title claims description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 133
- 238000004458 analytical method Methods 0.000 claims abstract description 30
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 16
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 62
- 238000005286 illumination Methods 0.000 claims description 39
- 238000001514 detection method Methods 0.000 claims description 30
- 239000012472 biological sample Substances 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 3
- 208000005228 Pericardial Effusion Diseases 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000003567 ascitic fluid Anatomy 0.000 claims description 3
- 230000000112 colonic effect Effects 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 210000002445 nipple Anatomy 0.000 claims description 3
- 210000004912 pericardial fluid Anatomy 0.000 claims description 3
- 210000004910 pleural fluid Anatomy 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 210000002358 circulating endothelial cell Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract description 73
- 229910052759 nickel Inorganic materials 0.000 abstract description 36
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 210000004881 tumor cell Anatomy 0.000 abstract description 22
- 230000005291 magnetic effect Effects 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 201000009030 Carcinoma Diseases 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000001574 biopsy Methods 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001444 catalytic combustion detection Methods 0.000 description 15
- 206010036618 Premenstrual syndrome Diseases 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 12
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000001427 coherent effect Effects 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011554 ferrofluid Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000002546 full scan Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 2
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- 241001502050 Acis Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000037323 Rare tumor Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 238000000627 alternating current impedance spectroscopy Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 108010053098 biotin receptor Proteins 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000207 volumetry Methods 0.000 description 1
Classifications
-
- G01N15/1433—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Definitions
- Automated image analysis systems have been used to reduce subjective errors in cell classification between different operators in manual methods, but such prior art systems without preliminary cell enrichment steps still inherently lack sensitivity.
- Several automated cell-imaging systems have been described or are commercially available for cell analysis.
- the system developed by Chromavision, ACISTM or Automated Cellular Imaging System uses colorimetric pattern recognition by microscopic examination of prepared cells by size, shape, hue and staining intensity as observed by an automated computer controlled microscope and/or by visual examination by a health care professional.
- the system uses examination of cells on microscope slides and was designed for tissue sections.
- Epithelial cells are not present in blood under normal circumstances. In patients with epithelial derived cancer (carcinomas) cancer cells can be shed into the blood. These cells are rare in peripheral blood and exhibit a large dynamic range from patient to patient. Tumor cells can be present in blood of carcinoma patients at extremely low frequencies ( ⁇ 10cells/ml_).
- Flow cytometry and/or fluorescence microscopy are analytical methods frequently used for analyzing the prepared samples. Flow cytometry has the advantage that it is sensitive and reproducible but it lacks the ability to simultaneously assess the immunophenotype and morphological features of the detected cells.
- fluorescence activated cell sorting FACS
- FACS fluorescence activated cell sorting
- Fluorescence microscopy has the disadvantage that considerable and variable cell losses are associated with the preparation of the sample slides for microscopic analysis. However it has the advantage that a cell can be visually confirmed as having features consistent with malignancy.
- CTC circulating tumor cells
- the present invention seeks to improve upon the aforementioned methodologies, and to provide simple and efficient means and methods for automated imaging of objects that can be used, for example, in conjunction with high sensitivity immunophenotyping, to permit detection, enumeration and accurate classification of rare target species, such as CTC in blood or other fluids.
- the present invention is a cell analyzer that differentiates immunomagnetically cells that are aligned on Nickel lines while passing through a focused laser beam.
- a conventional CD player objective was used to focus a laser-diode onto the magnetically aligned cells.
- An optical focus and tracking system analogous to that used in a CD player was used to scan along the lines.
- the emitted fluorescence signals were projected onto, and measured by, photomultiplier tubes.
- the absolute and relative cell populations identified by the instrument system correlated well with the numbers obtained with a standard flow cytometer or hematology analyzer.
- the features of the instrument system were expanded to demonstrate the potential for rare cell analysis by building on its sensitivity to measure immunofluorescence signals. This was accomplished through the addition of the ability to revisit the events of interest, and providing bright field and fluorescent images of these objects.
- a further embodiment of the invention includes a scanning mirror to deflect the illumination sources. As the objects of interest pass through illumination, a "rastered" pattern is formed across the objects, which is subsequently detected and transformed into a more detailed image of the object, creating a raster image.
- FIG. 1 diagrams the optical layout of the instrument system.
- DCLP dichroic long pass filter
- DCSP dichroic short pass filter
- PMT Photomultiplier Tube
- Figure 2 shows the sample chamber and magnetic design.
- Panel A is the sample chamber and plug to seal the chamber after filling.
- Panel B is the magnetic fixture that holds the sample chamber in position and move magnetically labeled objects to the upper surface of the chamber.
- a 3mm space separates the two angled magnets depicted black. The magnets are yoked by steel depicted gray.
- Panel C is a computer simulation of magnetically labeled cells present in the chamber. The dotted lines in the chamber represent the trajectory of randomly positioned magnetically labeled cells that move to the surface under influence of the magnetic gradient.
- Panel D is a magnification of the simulation shown in Panel C illustrating the trajectory of magnetically labeled cells once they approach the surface of the chamber.
- Figure 3 is a photomicrograph of PC3 cells alignment between Nickel lines. The relative size and distribution of the three laser spots are indicated in the figure (magnification 200 X)
- Figure 4 diagrams the configuration of laser scanning that results in rastering.
- Figure 5 shows the distribution of the cell size of circulating tumor cells. Tumor cell sizes of 1030 cells identified by a fluorescent microscope system in the blood of 8 carcinoma patients
- Figure 6 shows the results of the analysis of 7.5 ml blood sample spiked with tumor cells.
- Panel A shows the 2-dimensional dot plot of CK-PE versus CD45-APC: 295 tumor cells, 126 leukocytes and 11 CD45+, CK+ cells were detected in the sample. Approximately 300 cells of the prostate cell line PC3 were spiked into 7.5 ml of blood.
- Panel B shows an acquired waveform of the CK-PE signal.
- Panel C shows a bright field image of an object.
- Panel D shows the nuclear image of the object in panel C
- FIG. 7 diagrams an alternative optical layout of the cell tracks system.
- DCLP dichroic long pass filter
- DCSP dichroic short pass filter
- PMT Photomultiplier Tube
- Figure 8 shows a scanned image and the corresponding intensity profile for a static laser (A & B) and a scanning laser (C & D).
- Figure 9 diagrams the imaging subsystem (A), and shows a bright field image (B), and a laser scanned DAPI image (C & D).
- Figure 10 shows the analysis of the system (A) that has found a tumor cell candidate. The system then revisits this object and performs bright field imaging (B), scanning laser imaging (C), and combines the images into one (D).
- B bright field imaging
- C scanning laser imaging
- D combines the images into one
- Figure 11 shows bright field images of objects of interest that are revisited using the encoder position of the Y-stage recorded with each data point.
- This invention provides devices and methods that permit the application of novel imaging capabilities to such systems as the CellTracksTM cell analysis system as described by Tibbe eta/. (Nature Biotech. 17, 1210-13, 1999).
- the magnetically labeled cells are aligned along ferromagnetic lines of nickel (Ni) and are scanned by a laser focused by means of a conventional objective lens such as from a compact disk player. Since the cells have been selectively stained with one or more fluorescent labels, the measured fluorescence emissions and the intensities can be used to identify or classify the cell type.
- Epithelium derived tumor cells in peripheral blood are extremely rare but can be present in the blood of cancer patients.
- the certainty that an event present in a biological sample is an epithelial cell with the assumed characteristics diminishes with the number of events in the analysis gate. Additional and preferably independent information on the individual events aids in the correct classification of the event as an epithelium derived tumor cell.
- epithelial cells will be immunomagnetically selected from 7.5mL of blood and magnetically aligned in a sample chamber between a series of parallel thin film nickel lines. The CD head scans along all nickel lines and captures the fluorescence signals of the objects between the lines. Objects that immunophenotypically classify as epithelial tumor cells are revisited for imaging to determine if the identified objects indeed classify as epithelial tumors cells or as debris derived from epithelial cells.
- target bioentities refers to a wide variety of materials of biological or medical interest and can be distinguished from “non-target” materials that are present in the specimen. Examples include hormones, proteins, peptides, lectins, oligonucleotides, drugs, chemical substances, nucleic acid molecules, (e.g., RNA and/or DNA) and particulate analytes of biological origin, which include bioparticles such as cells, viruses, bacteria and the like.
- rare cells such as fetal cells in maternal circulation, or circulating cancer cells may be efficiently isolated from non-target cells and/or other bioentities, using the apparatus and methods of the present invention.
- biological specimen or “biological sample” may be used interchangeably, and refer to a small potion of fluid or tissue taken from a human test subject that is suspected to contain biological entities (or bioentities) of interest, and is to be analyzed.
- a biological specimen refers to the fluidic portion, the cellular portion, and the portion containing soluble material.
- Biological specimens or biological samples include, without limit bodily fluids, such as peripheral blood, tissue homogenates, nipple aspirates, colonic lavage, sputum, bronchial (alveolar) lavage, pleural fluids, peritoneal fluids, pericardial fluids, urine, and any other source of cells that is obtainable from a human test subject.
- An exemplary tissue homogenate may be obtained from the sentinel node in a breast cancer patient.
- Biological entities refer to objects of interest, as would be understood from the previous description.
- determinant when used in reference to any of the foregoing target bioentities, refers broadly to chemical mosaics present on macromolecular antigens that often induce an immune response. Determinants may also be used interchangeably with “epitopes”.
- a determinant refers to that portion of the target bioentity involved in, and responsible for, selective binding to a specific binding substance (such as a ligand or reagent), the presence of which is required for selective binding to occur.
- determinants are molecular contact regions on target bioentities that are recognized by agents, ligands and/or reagents having binding affinity therefore, in specific binding pair reactions.
- binding pair includes antigen-antibody, receptor-hormone, receptor-ligand, agonist-antagonist, lectin-carbohydrate, nucleic acid (RNA or DNA) hybridizing sequences, Fc receptor or mouse IgG-protein A, avidin-biotin, streptavidin-biotin and virus-receptor interactions.
- detectably label is used to herein to refer to any substance whose detection or measurement, either directly or indirectly, by physical or chemical means, is indicative of the presence of the target bioentity in the test sample.
- detectable labels include, but are not limited to the following: molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, reflectance, light scatter, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; molecules or ions detectable by their nuclear magnetic resonance or paramagnetic properties. Included among the group of molecules indirectly detectable based on light absorbance or fluorescence, for example, are various enzymes which cause appropriate substrates to convert (e.g., from non-light absorbing to light absorbing molecules, or from non-fluorescent to fluorescent molecules).
- Analysis can be performed using any of a number of commonly used platforms, including multiparameter flow cytometry, immunofluorescent microscopy, laser scanning cytometry, bright field base image analysis, capillary volumetry, spectral imaging analysis, manual cell analysis, CellSpotter® analysis, CellTracksTM analysis, and automated cell analysis. ⁇
- Biospecific ligands and reagents have specific binding activity for their target determinant yet may also exhibit a low level of non-specific binding to other sample components.
- the present system was designed to identify rare cells.
- the term "rare cells” is defined herein as cells that are not normally present in biological specimens, but may be present as an indicator of an abnormal condition, such as infectious disease, chronic disease, injury, or pregnancy. Rare cells also refer to cells that may be normally present in biological specimens, but are present with a frequency several orders of magnitude less than cells typically present in a normal biological specimen.
- the detection and enumeration procedure used herein is further described in US#6,365,362, which is incorporated by reference.
- the optics of the present system includes an illumination source and a detector.
- the illumination means may be narrow-spectrum lasers or LEDs. It may also be a broad- spectrum white light source, where light is passed through narrow spectrum filters to achieve the desired wavelengths.
- the detection components consist of two-dimensional arrays of detector elements. Examples of such a detector array include PMTs and CCDs. However, persons skilled in the art will appreciate that other illumination and detection means may be used in this invention.
- Cells were transferred to a sample chamber (described in US #6,136,182 and US 2002/0109838, incorporated by reference herein) and magnetically aligned between 90 parallel 15 ⁇ m-wide Nickel lines on the inside surface of the sample chamber, as described in US #5,985,153, which is incorporated by reference herein.
- the CD head scans along all Nickel lines with an illuminating means in less than 5 minutes, capturing the fluorescence signals of the objects between the lines with a detection means. Cells maintain their position by magnetic force, which creates the possibility to revisit cells of interest.
- the imaging techniques used in this invention are based on those described in the commonly owned application PCT/US02/00203, which is incorporated by reference herein.
- PE The high extinction coefficient and quantum yield and the large Stokes shifts of PE makes it an excellent choice as the fluorochrome for labeling the cytokeratin antibody that identifies the cytoskeletal proteins in the epithelial cells.
- a 532nm light source was chosen to excite PE as it provides a 6-fold increase in signal to noise ratio as compared to 488nm excitation.
- the time a cell is exposed to the laser spot is orders of magnitude larger compared to a flow cytometer and more photons can thus be collected which explains the higher sensitivity of the system.
- PE can be excited by the 405nm laser line. However, we have not yet compared the signal to noise ratio with both excitation sources at different scanning speeds.
- the 635nm light source was chosen to excite APC thereby avoiding any overlap between the excitation and emission spectra of PE.
- the CD45-APC permits the discrimination of the leukocytes carried over through the enrichment procedure from the epithelial cells. More importantly it avoids identifying the leukocytes that non-specifically bind to CK- PE as epithelial cells. Leukocytes can be attached to epithelial derived tumor cells in blood. This phenomenon would result in a relevant CK+ and CD45+ object that can be distinguished from the non-relevant objects by the waveform of the fluorescent signals in concert with the images of the cells.
- the immunophenotype, spatial distributions of the digitized fluorescence signals and the bright field and fluorescence images, measured in the system of the present invention enables the identification of epithelial cells present at low frequency in blood and further enables sub classification of these cells such as intact, damaged or epithelial cell debris. While in this study carcinoma cells lines were used to demonstrate performance of the instrument, it is clear that the instrument can be used for a variety of cell analyses including the detection of other rare events, such as endothelial cells in blood, fetal cells in maternal blood, bacteria in blood or other fluids.
- the sample preparation process can be modified to be specific to any target of interest (by ferrofluid selection) and the staining of cells would have to be compatible with the laser wavelength and filter selections established within the system.
- the system of the present invention was calibrated using 6 ⁇ m Deep Red fluorescent beads (Molecular Probes, Eugene, Oregon) that were labeled with superparamagnetic ferrofluids (Immunicon, Huntingdon Valley, PA) as described in US #6,120,856, which is incorporated by reference herein.
- the magnetic beads were used at a concentration of 3000/mL and were placed in a sample chamber (320 ⁇ l) prior to analyzing.
- a semi-automated sample preparation system (CellPrepTM, as described in US#10/081,996, incorporated by reference herein) was used to process blood samples.
- CellPrepTM a semi-automated sample preparation system
- 7.5mL of whole blood is incubated with EpCAM (epithelial cell adhesion molecule) labeled immunomagnetic particles (ferrofluids described above).
- EpCAM epihelial cell adhesion molecule
- the EpCAM antigen is expressed on cells of epithelial origin, but not on blood cells.
- a series of incubation, separation, and resuspension steps results in a sample of 320 ⁇ L placed in a sample chamber (as described in US# 10/074,900, incorporated by reference herein) that is held between two poles of a specially designed permanent magnet fixture (as described in US#6,136,182, incorporated by reference herein).
- the sample contains immunomagnetically- selected cells labeled fluorescently with anti-cytokeratin conjugated to Phycoerythrin (CK-PE), anti- CD45 conjugated to Allophycocyanin (CD45-APC) and the nucleic acid specific dye DAPI (4,6- diamidino-2-phenylindole).
- the anti-cytokeratin recognizes low molecular weight keratins 4, 6, 8, 10, 13, and 18, present in cells of epithelial origin.
- the anti-CD45 identifies leukocytes and DAPI stains the cell nucleus.
- the sample chamber consists of a molded polystyrene housing on which a glass coverslip is attached that bears a series of parallel thin film Nickel lines (Metrigraphics, Wilmington, MA).
- the glass top is affixed to the chamber body with an optical grade UV curable adhesive (Dymax, Torrington, CT) thus forming the chamber cavity.
- the dimensions of the chamber 30mm X 4mm X 2.7mm, yield an internal fluid volume of 324 ⁇ L.
- the sample is dispensed into the chamber through an entry port and capped off by the operator to seal out air and allow the chamber to be placed on the instrument for analysis. Computer simulation was used to determine the optimal magnet angle and distance of the sample chamber surface to obtain the most uniform field gradient.
- FIG 2A shows the sample chamber and the magnet yoke assembly that holds the chamber between the two magnets is shown in Figure 2B.
- Figure 2B For uniform cell distribution, it was necessary to determine the optimal angle of the magnets and the optimal position of the chamber with respect to the two angular shaped magnets, as described in US#6,136,182.
- FIG. 2C shows such a simulation.
- the chamber is outlined between the North (N) and South (S) pole of the magnets and the dashed lines indicate the trajectory of magnetically labeled cells.
- Figure 2D shows a magnification of the trajectory within the chamber as well as the alignment trajectory when the cells are near the Nickel lines. Additionally, the magnetic fixture provides further enrichment of the sample by separating the magnetically bound material from non-magnetic constituents in the 320 ⁇ L sample.
- the optical system must provide five functions:
- Figure 1 shows the optical system that consists of three lasers for excitation and four photomultipliers for detecting the fluorescent signals from the various fluorescent labels.
- the three laser beams are combined by dichroic beamsplitters and focused by a CD objective onto the plane of the Nickel lines.
- Each laser includes anamorphic beam shaping optics to create an elongated focused laser spot at the plane of the cells.
- the three laser spots are spaced apart with major axis orientation perpendicular to the Nickel lines as shown in Figure 3.
- a magnetic actuation support for the CD objective maintains alignment by moving the objective along two axes, along the optical axis for focus and perpendicular to the Nickel lines for tracking.
- the 532nm laser reflection from the Nickel lines is detected through a quarter-wave plate and polarizing beamsplitter by tracking and focus detectors, which provide servo signals for actuation of the CD objective.
- the system aligns the chamber in preparation for scanning and positions the sample so that the CD objective is aligned on the first pair of Nickel lines.
- the sample is then moved by a stepper motor in the y-direction (O.l ⁇ m stepsize) along the length of the sample chamber while the CD objective and servo electronics maintain proper focus and tracking.
- the instrument indexes the sample in the x-direction by a stepper motor (O.l ⁇ m stepsize) to the next pair of adjacent Nickel lines and repeats the y-direction scanning in the opposite direction. The process is repeated until all 90 Nickel line pairs have been scanned. At lOmm/sec, the time required to scan all 90 lines is 4.5 minutes.
- each photomultiplier collects light through a filter and a pinhole, which is parallel to the plane of the Nickel lines. Each pinhole eliminates reflected light from the Nickel lines and views only fluorescence from a selected laser. Minimal crosstalk between fluorescent signals is ensured by the spectral and spatial separation provided by each filter and pinhole.
- the fluorescence signals are converted to analog signals by a 16-bit analog-to-digital converter board.
- the multiplexed signals are sampled at a sampling frequency of 25 kHz for a speed in the y-direction of lOmm/sec. For an epithelial cell with a typical diameter of 12 ⁇ m, this sampling rate corresponds to 30 data points across the cell.
- the stage which moves the sample under the CD objective, has been equipped with a quadrature encoder (Reneshaw, Gloucestershire, UK) that has a resolution of 0.8 microns.
- the encoder signals are connected to a counter present on the same analog to digital converter board that samples the photomultiplier signals. Fluorescent signals and y-position information are recorded simultaneously during scanning. The discrete line number on which a specific event is recorded and the positional information in the x-direction are also recorded.
- Steps 4-7 are continued for each line until the entire sample has been scanned.
- the total scan is 90 lines, times 30mm/line, which results in a 2.7m scan for each sample.
- Images of selected cells are digitized with a CCD array using the CD objective and imaging optics.
- fluorescent imaging is accomplished with the lasers.
- an angular scanning mirror scans the laser spots, over the cell as the CCD integrates emitted photons. Using this scanning technique, even very dim fluorescent objects are imaged with excellent signal to noise and resolution.
- FIG. 5 shows the cell size distribution ranging from approximately 5-30 ⁇ m with a mean diameter of 11.3 ⁇ m. This posed a problem of selecting a standard line spacing that could accommodate this variation in diameter. If the Nickel lines are spaced to accommodate the larger cells, then there is the risk that smaller cells will occupy the same lateral space or form clusters and be seen as a single event when scanned in the y-direction. If too narrow a space, then the Nickel lines will obscure a large percentage of the cells and compromise imaging of the cell. Criteria were selected for the lines to allow for >95% of the population to be >85% visible.
- a line spacing of 15 ⁇ m With a chamber width of 2.7mm and a 15 ⁇ m width of the Nickel, a total of 90 lines are on the chamber surface.
- the traced fluorescence signals of the objects, and images obtained after revisiting the objects, are analyzed to identify events that are smaller and laterally aligned or clustered between the lines.
- a large dynamic range of circulating tumor cells (CTC) ranging from 1 to 5,000 cells per 7.5mL sample was observed in patient samples.
- Leukocytes carried over through the sample preparation procedure from 57 blood samples ranged from 428-17,718 cells with a mean of 5,203 and a median of 1,857 leukocytes.
- the 90 lines on the chamber surface provide a linear space of 2.7 meters for capturing cells. Assuming an average tumor cell size of 12 ⁇ m and allowing an occupancy of 10%, the chamber capacity is 22,500 tumor cells and is well within the dynamic range of both captured tumor cells and leukocytes.
- PC3 prostate carcinoma tissue culture cell line
- PC3 cells Approximately 300 PC3 cells were spiked into 7.5mL of blood and processed with CellPrepTM as described above. When the sample is dispensed into the sample chamber while being held in the magnetic field, the immunomagnetically labeled cells are drawn to the upper inside surface of the chamber by magnetic forces from the permanent magnets. A bright field image of the aligned PC3 cells is shown in Figure 3.
- Figure 6 shows the analysis of the sample.
- the 2-dimensional dot plot in Figure 6A shows the fluorescence signals of CK-PE and CD45-APC.
- the tumor cell candidates (PC3-cells) staining with CK-PE and lacking CD45-APC can be clearly discriminated from the leukocytes staining with CD45-APC and lacking CK-PE.
- Events that stain with cytokeratin as well as CD45 are tumor cells that stain non- specifically with CD45, leukocytes that non-specifically stain with Cytokeratin or debris.
- Figure 6B shows the waveform of the CK-PE signal for one of the events within the tumor cell region.
- the size of the event is 20 ⁇ m as provided by the encoder position along the line in concert with the fluorescence signal.
- the distribution of the cytokeratin throughout the cytoplasm shows a demarcation in the first part of the signal that coincides with the nucleus of the cell. If the waveform of this particular event strongly suggests that this indeed is a cell, the system relocates to this position in the chamber to obtain bright field and nuclear images of the object.
- the sample is illuminated with a blue LED positioned below the sample chamber and the CCD captures a bright field image of the object.
- the bright field image shown in Figure 6C clearly shows the typical features exhibited by a cell. To verify that the cell indeed contains a nucleus, an image of the nuclear staining of DAPI is obtained.
- the scanning mirror ( Figure 1) distributes the light of the violet laser with an angle scanning range of 5mrad at a frequency of 500Hz over the location of the object and an image is taken with the CCD camera.
- the fluorescent image of the DAPI is shown in Figure 6D.
- the nucleus clearly is contained within the outline of the cell shown in Figure 6C.
- cells are imaged with laser illumination to avoid the additional cost, low intensity, and short lifetime of broadband light sources.
- the long coherence length of lasers and light reflections in the imaging system contribute coherent noise and speckle in the image.
- the Gaussian intensity profile of the laser beam does not provide uniform illumination of the object. Both of these problems with coherent illumination are overcome by moving the laser spot across the object as the CCD array integrates the light. Movement of the source during exposure washes out the coherent noise in the image.
- Any angular scanning means such as a scanning mirror, rotating mirror, electro-optic or acousto-optic deflector, or electro-refractive device could be used to deflect the beam by a small angle, providing motion of the focused laser spot at the object plane. By driving this device with a periodic signal, the spot is scanned back and forth over the object.
- Figure 1 shows the optical configuration for the instrument.
- Three lasers illuminate the magnetically confined object and four PMT detectors measure fluorescence from the object as it passes through each laser spot in the focal plane of the objective lens.
- the three laser beams are combined by dichroic beamsplitters and focused by a CD objective onto the plane of the nickel lines.
- Each laser includes anamorphic beam shaping optics to create an elongated focused laser spot at the plane of the cells.
- the three laser spots are spaced apart with major axis orientation perpendicular to the nickel lines.
- a magnetic actuation support for the CD objective maintains alignment by moving the objective along two axes, along the optical axis for focus and perpendicular to the nickel lines for tracking.
- the 532nm laser reflection from the nickel lines is detected through a quarter-wave plate and polarizing beamsplitter by tracking and focus detectors, which provide servo signals for actuation of the CD objective.
- a corresponding PMT detection means measures the fluorescence.
- Each PMT collects light through a filter and a pinhole, which is conjugate to the plane of the nickel lines.
- Each pinhole eliminates reflected light from the nickel lines and views only fluorescence from a selected laser. Minimal cross talk between fluorescent signals is insured by the spectral and spatial separation provided by each filter and pinhole.
- the object is moved into a laser spot, which is scanned back and forth by a scanning mirror.
- the total angular scan range is appropriate for the size of illumination region and focal length of the objective.
- the scanning mirror reflects the laser beams through a beamsplitter and objective lens to the object plane.
- the fluorescence or scattered light from the object passes back through the same objective lens and beamsplitter to a second lens and CCD array for imaging.
- the scanning frequency must be sufficient to provide many full scans during the integration time of the CCD array. If the mirror passes through only a few full scans and one partial scan, the integrated illumination over the object will not be uniform.
- the CCD should only collect photons during an integral number of full scans, or many full scans plus one partial scan. Then the partial scan contribution becomes a small portion of the total integrated current on each CCD pixel.
- the optical system will scan more tracks to measure other fluorescent objects with the PMT detectors. Therefore, the static position of the scanning device must return the system to the original optical alignment of the PMT pinholes with the laser beams and nickel line gap.
- the system shown in Figure 1 ensures this alignment by placing the scanning device and CCD array after the 3 band filter which splits the lasers and fluorescent beams going to the PMT detectors. Variations of the scanning mirror static position between successive imaging sessions will not effect the alignment of pinholes with the laser spots and nickel lines.
- Figure 4 shows two configurations for laser scanning.
- the instrument system uses an elongated laser spot, which spans adjacent nickel lines, to excite fluorescence of objects between the lines and to provide tracking and focus servo signals from light reflected by the lines.
- this elongated laser spot is scanned along the Y-axis to illuminate an extended region between the nickel lines. Illumination uniformity is maintained by scanning over a distance that is larger than width of the laser spot. Due to the high intensity of the laser spot, even very dim fluorescent objects are imaged with excellent signal to noise and resolution by using this scanning technique.
- the object plane is moved out of the focal plane of the laser to increase the illumination area and intensity uniformity over the region of interest.
- the scanning mirror moves this broad spot back and forth across the object, eliminating coherent noise and structure in the image.
- the broad beam in Figure 4B, covers a large region when scanned in either the X or Y direction.
- the coherent noise in the image may be reduced to acceptable levels with very small motion of the spot.
- removal of the spot intensity profile requires a larger scan amplitude.
- the CCD must integrate over many scans of the mirror to reduce the effect of a partial start or stop scan. The total of all scans must approach an integral number of scans as the scan number decreases to maintain image uniformity.
- the scanning technique could improve the resolution of the fluorescent signals from the PMT detectors.
- the laser beam in Figure 4A moves across a cell, it illuminates a large portion of the cell at any time.
- the fluorescent signal cannot accurately represent the small structural details of the cell.
- the Fourier spectrum of the nuclear stain fluorescent signals may differentiate between normal and tumor cells. To obtain the high frequencies of the cell structure requires interrogation of the cell with a small spot to provide resolution of the smaller components of the cell. A single scan of a small spot through the middle of the cell would provide high frequency response only over a small portion of the cell.
- the scanning mirror in Figure 1 is oriented to scan the laser spot in the X direction and provide the raster pattern.
- the optical system must remain locked on focus and track during the raster scan, and the spot of the tracking laser should not move in the X direction relative to the nickel lines.
- the focus and track laser beam must not pass through the scanning or deflection device to conserve servo alignment during the raster motion.
- the configuration shown in Figure 7 will allow one or more lasers to scan in the X or Y direction while another static laser provides the signals for the focus and track servos. In Figure 7, only the 405nm laser is scanned.
- a scanning mirror can be placed in the path of any laser, except for the tracking laser, to produce fluorescent images for that laser.
- the PMT which views the scanning laser spot will produce a raster fluorescent signal for the corresponding excited dye.
- This configuration also accommodates the CCD image scanning described in Figure 4A and 4B for the lasers which pass through the scanning device.
- Figure 8 shows a sample chamber that was loaded with a solution of DNA that was labeled with DAPI.
- the chamber is illuminated with the 405nm laser diode.
- the intensity profiles are speckled and narrow with the static laser, but are corrected with the scanning mirror. This is seen by the differences between 8A, the static laser image and 8B, the corresponding intensity profile, and 8C, the scanning laser image and 8D, its corresponding intensity profile.
- the scanning laser provides more uniform illumination and reduces the speckling effect by averaging the speckle while scanning.
- the imaging subsystem that is used for revisiting objects of interest is shown in Figure 9.
- the revisiting process uses a bright-field illumination system to further image objects of interest. Briefly, the procedure is:
- the mirror starts raster scanning to provide an uniform laser illumination of the region
- FIGs 9B, 9C, and 9D These steps can be seen in Figures 9B, 9C, and 9D.
- the bright field image is shown, where there are three objects of interest.
- the middle one is the subject of further analysis.
- Figure 9C shows the scanning laser image, which images the nucleus.
- the bright field and scanning laser images are combined.
- Figure 10 shows an analysis of the system, which has found a tumor cell candidate (10A). This object is then revisited for further analysis and confirmation.
- Figure 10B shows the bright field imaging of the object, using the subsystem described above. The scanning laser then images the object for nucleic acid, as shown in IOC. Finally, these two images are combined to give a complete picture of the object.
- Figure 11 shows various objects of interest as imaged by the bright field imaging subsystem. Different objects are labeled in each of the panels, pointing out ferrofluid lines, cells, and questionable areas that may or may not be real objects. However, just by viewing these images alone, one would not be able to easily classify them, as described in PCT/US02/26861, which is incorporated by reference herein. The next step would be to use the scanning laser at each of these objects to obtain further information that would be used for classification. By using the imaging system and methods described in this invention, these objects would be classified, providing the instrument operator with valuable information. Multicolor fluorescence intensity analysis permits the identification of rare tumor cell candidates. The addition of fluorescence signatures, bright field image and DAPI image permits the further classification into:
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002484730A CA2484730A1 (en) | 2002-05-03 | 2003-05-05 | Device and method for analytical cell imaging |
EP03728685A EP1501917A4 (en) | 2002-05-03 | 2003-05-05 | Device and method for analytical cell imaging |
JP2004501911A JP2005524833A (en) | 2002-05-03 | 2003-05-05 | Devices and methods for analytical cell imaging |
AU2003234459A AU2003234459A1 (en) | 2002-05-03 | 2003-05-05 | Device and method for analytical cell imaging |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37786802P | 2002-05-03 | 2002-05-03 | |
US60/377,868 | 2002-05-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003093795A2 true WO2003093795A2 (en) | 2003-11-13 |
WO2003093795A3 WO2003093795A3 (en) | 2004-10-21 |
Family
ID=29401578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/013842 WO2003093795A2 (en) | 2002-05-03 | 2003-05-05 | Device and method for analytical cell imaging |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1501917A4 (en) |
JP (1) | JP2005524833A (en) |
AU (1) | AU2003234459A1 (en) |
CA (1) | CA2484730A1 (en) |
WO (1) | WO2003093795A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1541993A2 (en) * | 2003-12-12 | 2005-06-15 | Hitachi Software Engineering Co., Ltd. | Fluorescent beads detecting method and apparatus |
WO2006017811A2 (en) | 2004-08-06 | 2006-02-16 | Compucyte Corporation | Multiple-color monochromatic light absorption and quantification of light absorption in a stained sample |
WO2006042369A1 (en) * | 2004-10-22 | 2006-04-27 | Fermiscan Australia Pty Limited | Analytical method and apparatus |
EP1804051A1 (en) | 2005-12-27 | 2007-07-04 | Wallac Oy | Instrumentation and Method for Optical Measurement of Samples |
WO2008012724A2 (en) * | 2006-07-20 | 2008-01-31 | Koninklijke Philips Electronics N.V. | Optical tracking and position determination for detection methods and systems |
CN102272581A (en) * | 2010-03-31 | 2011-12-07 | 古河电气工业株式会社 | Cell discrimination device and cell discrimination method |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8585971B2 (en) | 2005-04-05 | 2013-11-19 | The General Hospital Corporation | Devices and method for enrichment and alteration of cells and other particles |
US8895298B2 (en) | 2002-09-27 | 2014-11-25 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
CN104914078A (en) * | 2015-04-16 | 2015-09-16 | 南京昊控软件技术有限公司 | Large-range multi-point fluid concentration measuring system |
JP2019522181A (en) * | 2016-05-18 | 2019-08-08 | バイオサイテックス | New optical properties of fluorescent markers |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
EP3974387A1 (en) * | 2016-03-07 | 2022-03-30 | X-Zell Inc. | Compositions and methods for identifying rare cells |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007053245A2 (en) | 2005-09-20 | 2007-05-10 | Immunivest Corporation | Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes |
US9134237B2 (en) * | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
JP2009537021A (en) * | 2006-05-12 | 2009-10-22 | ベリデックス・リミテッド・ライアビリティ・カンパニー | Laser irradiation system in fluorescence microscopy |
US7782452B2 (en) * | 2007-08-31 | 2010-08-24 | Kla-Tencor Technologies Corp. | Systems and method for simultaneously inspecting a specimen with two distinct channels |
US8143600B2 (en) * | 2008-02-18 | 2012-03-27 | Visiongate, Inc. | 3D imaging of live cells with ultraviolet radiation |
JP5119114B2 (en) * | 2008-09-30 | 2013-01-16 | 富士フイルム株式会社 | Light source device and photographing device |
WO2012128841A2 (en) | 2011-03-24 | 2012-09-27 | Anpac Bio-Medical Science Co., Ltd. | Micro-devices for disease detection |
US20140073884A1 (en) | 2011-05-05 | 2014-03-13 | Anpac Bio-Medical Science Co., Ltd. | Apparatus for detecting tumor cells |
EP2729802B1 (en) * | 2011-07-07 | 2015-05-06 | Scripps Health | Method of analyzing cardiovascular disorders and uses thereof |
US9511152B2 (en) * | 2012-04-05 | 2016-12-06 | The Board Of Regents Of The University Of Texas System | Multicolored pH-activatable fluorescence nanoplatform |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034613A (en) * | 1989-11-14 | 1991-07-23 | Cornell Research Foundation, Inc. | Two-photon laser microscopy |
US5127730A (en) * | 1990-08-10 | 1992-07-07 | Regents Of The University Of Minnesota | Multi-color laser scanning confocal imaging system |
US5479252A (en) * | 1993-06-17 | 1995-12-26 | Ultrapointe Corporation | Laser imaging system for inspection and analysis of sub-micron particles |
US5691839A (en) * | 1993-04-15 | 1997-11-25 | Kowa Company Ltd. | Laser scanning optical microscope |
US5698397A (en) * | 1995-06-07 | 1997-12-16 | Sri International | Up-converting reporters for biological and other assays using laser excitation techniques |
-
2003
- 2003-05-05 JP JP2004501911A patent/JP2005524833A/en active Pending
- 2003-05-05 CA CA002484730A patent/CA2484730A1/en not_active Abandoned
- 2003-05-05 WO PCT/US2003/013842 patent/WO2003093795A2/en not_active Application Discontinuation
- 2003-05-05 EP EP03728685A patent/EP1501917A4/en not_active Withdrawn
- 2003-05-05 AU AU2003234459A patent/AU2003234459A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034613A (en) * | 1989-11-14 | 1991-07-23 | Cornell Research Foundation, Inc. | Two-photon laser microscopy |
US5127730A (en) * | 1990-08-10 | 1992-07-07 | Regents Of The University Of Minnesota | Multi-color laser scanning confocal imaging system |
US5691839A (en) * | 1993-04-15 | 1997-11-25 | Kowa Company Ltd. | Laser scanning optical microscope |
US5479252A (en) * | 1993-06-17 | 1995-12-26 | Ultrapointe Corporation | Laser imaging system for inspection and analysis of sub-micron particles |
US5698397A (en) * | 1995-06-07 | 1997-12-16 | Sri International | Up-converting reporters for biological and other assays using laser excitation techniques |
Non-Patent Citations (1)
Title |
---|
See also references of EP1501917A2 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11052392B2 (en) | 2002-09-27 | 2021-07-06 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US8895298B2 (en) | 2002-09-27 | 2014-11-25 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US10081014B2 (en) | 2002-09-27 | 2018-09-25 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
EP1541993A2 (en) * | 2003-12-12 | 2005-06-15 | Hitachi Software Engineering Co., Ltd. | Fluorescent beads detecting method and apparatus |
EP1541993A3 (en) * | 2003-12-12 | 2005-08-10 | Hitachi Software Engineering Co., Ltd. | Fluorescent beads detecting method and apparatus |
WO2006017811A3 (en) * | 2004-08-06 | 2006-06-15 | Compucyte Corp | Multiple-color monochromatic light absorption and quantification of light absorption in a stained sample |
US7468796B2 (en) | 2004-08-06 | 2008-12-23 | Compucyte Corporation | Multiple-color monochromatic light absorption and quantification of light absorption in a stained sample |
WO2006017811A2 (en) | 2004-08-06 | 2006-02-16 | Compucyte Corporation | Multiple-color monochromatic light absorption and quantification of light absorption in a stained sample |
WO2006042369A1 (en) * | 2004-10-22 | 2006-04-27 | Fermiscan Australia Pty Limited | Analytical method and apparatus |
US10786817B2 (en) | 2005-04-05 | 2020-09-29 | The General Hospital Corporation | Devices and method for enrichment and alteration of cells and other particles |
US8585971B2 (en) | 2005-04-05 | 2013-11-19 | The General Hospital Corporation | Devices and method for enrichment and alteration of cells and other particles |
US9956562B2 (en) | 2005-04-05 | 2018-05-01 | The General Hospital Corporation | Devices and method for enrichment and alteration of cells and other particles |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
EP1804051A1 (en) | 2005-12-27 | 2007-07-04 | Wallac Oy | Instrumentation and Method for Optical Measurement of Samples |
US10435751B2 (en) | 2006-06-14 | 2019-10-08 | Verinata Health, Inc. | Methods for the diagnosis of fetal abnormalities |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US11781187B2 (en) | 2006-06-14 | 2023-10-10 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US11674176B2 (en) | 2006-06-14 | 2023-06-13 | Verinata Health, Inc | Fetal aneuploidy detection by sequencing |
US11261492B2 (en) | 2006-06-14 | 2022-03-01 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US9017942B2 (en) | 2006-06-14 | 2015-04-28 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
US9273355B2 (en) | 2006-06-14 | 2016-03-01 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US9347100B2 (en) | 2006-06-14 | 2016-05-24 | Gpb Scientific, Llc | Rare cell analysis using sample splitting and DNA tags |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10155984B2 (en) | 2006-06-14 | 2018-12-18 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US10041119B2 (en) | 2006-06-14 | 2018-08-07 | Verinata Health, Inc. | Methods for the diagnosis of fetal abnormalities |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
WO2008012724A3 (en) * | 2006-07-20 | 2008-05-02 | Koninkl Philips Electronics Nv | Optical tracking and position determination for detection methods and systems |
WO2008012724A2 (en) * | 2006-07-20 | 2008-01-31 | Koninklijke Philips Electronics N.V. | Optical tracking and position determination for detection methods and systems |
US9404157B2 (en) | 2008-09-20 | 2016-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US9353414B2 (en) | 2008-09-20 | 2016-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US10669585B2 (en) | 2008-09-20 | 2020-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8296076B2 (en) | 2008-09-20 | 2012-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuoploidy by sequencing |
US8682594B2 (en) | 2008-09-20 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
CN102272581A (en) * | 2010-03-31 | 2011-12-07 | 古河电气工业株式会社 | Cell discrimination device and cell discrimination method |
CN104914078A (en) * | 2015-04-16 | 2015-09-16 | 南京昊控软件技术有限公司 | Large-range multi-point fluid concentration measuring system |
EP3974387A1 (en) * | 2016-03-07 | 2022-03-30 | X-Zell Inc. | Compositions and methods for identifying rare cells |
JP2019522181A (en) * | 2016-05-18 | 2019-08-08 | バイオサイテックス | New optical properties of fluorescent markers |
Also Published As
Publication number | Publication date |
---|---|
JP2005524833A (en) | 2005-08-18 |
CA2484730A1 (en) | 2003-11-13 |
AU2003234459A8 (en) | 2003-11-17 |
EP1501917A2 (en) | 2005-02-02 |
WO2003093795A3 (en) | 2004-10-21 |
AU2003234459A1 (en) | 2003-11-17 |
EP1501917A4 (en) | 2006-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060094109A1 (en) | Device and method for analytical cell imaging | |
WO2003093795A2 (en) | Device and method for analytical cell imaging | |
US7282180B2 (en) | Devices and methods to image objects | |
AU2008249152B2 (en) | Devices and methods to image objects | |
US7764821B2 (en) | Methods and algorithms for cell enumeration in a low-cost cytometer | |
US7277569B2 (en) | Apparatus and method for detecting and locating rare cells | |
US8189899B2 (en) | Methods and algorithms for cell enumeration in a low-cost cytometer | |
US5547849A (en) | Apparatus and method for volumetric capillary cytometry | |
US8128890B2 (en) | Methods and algorithms for cell enumeration in a low-cost cytometer | |
US9134237B2 (en) | High sensitivity multiparameter method for rare event analysis in a biological sample | |
JP2018185316A (en) | Methods of detecting circulating tumor cells and methods of diagnosing cancer in mammalian subjects | |
JP2001516050A (en) | Apparatus and method for imaging a sample labeled with a light scattering material | |
EP1656545B1 (en) | Devices and methods to image objects by time delay integration | |
US20200379227A1 (en) | Method For Analyzing Fluorescent Particles in an Immunoassay | |
Kagan et al. | CellTracks: Cell analysis system for rare cell detection | |
US20120202189A1 (en) | Rapid, semi-automated method to detect respiratory virus infected cells in direct specimens | |
AU2002245215A1 (en) | Devices and methods to image objects | |
Hsieh et al. | Location and biomarker characterization of circulating tumor cells | |
Verrant et al. | i, United States Patent (10) Patent No.: US 7,764,821 B2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004501911 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003728685 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2484730 Country of ref document: CA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2003728685 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003728685 Country of ref document: EP |